NCT01319045View on ClinicalTrials.gov

Iloprost for the Treatment of Pulmonary Hypertension in Adults With Congenital Heart Disease

NATerminatedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

May 31, 2013

Study Completion Date

May 31, 2013

Conditions
Pulmonary Arterial HypertensionCongenital Heart DiseaseEisenmenger's Syndrome
Interventions
DRUG

Iloprost

Aerosolized iloprost, 5 mcg/dose x 6 doses daily for 3 months

Trial Locations (1)

90095

Ronald Reagan UCLA Medical Center, Los Angeles

Sponsors

Collaborators (1)

Actelion
All Listed Sponsors
collaborator

Actelion

INDUSTRY

lead

University of California, Los Angeles

OTHER